Shares of Mylan N.V. (NASDAQ:MYL) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 0.16% to close at $37.82. Mylan N.V. (MYL) reported the launch of the authorized generic for EpiPen Auto-Injector at a wholesale acquisition cost of $300 per epinephrine injection, USP two-pack.
The company said the authorized generic will be accessible starting next week through retail channels.
Mylan said it is also offering a savings card for eligible patients with commercial health insurance, providing up to $25 off the out-of-pocket cost for the authorized generic. Moving forward to saw long-term intention, the experts calculate Return on Investment of 8.20%. The stock is going forward its fifty-two week low with 12.56% and lagging behind from its 52-week high price with -31.87%. MYL last month stock price volatility remained 2.95%.
BCE Inc. (NYSE:BCE) reported that 2,254,079 of its 25,000,000 fixed-rate Cumulative Redeemable First Preferred Shares, Series AK have been tendered for conversion on December 31, 2016, on a one-for-one basis, into floating-rate Cumulative Redeemable First Preferred Shares, Series AL. Consequently, BCE will issue 2,254,079 new Series AL Preferred Shares as of December 31, 2016.
The Series AL Preferred Shares will pay for each quarterly period beginning with the quarterly period from and including December 31, 2016 up to but excluding March 31, 2017, as and when declared by the Board of Directors of BCE, a quarterly floating cash dividend based on the T-Bill Rate for such quarterly period plus 1.88%, calculated in accordance with the articles of BCE.